YOLFTbeta
CALIWAY BIOPHARMACEUTICALS CO L

CALIWAY BIOPHARMACEUTICALS CO L

6919 · TW · Healthcare / Biotechnology

70.10TWD+0.10 (+0.14%)

Price History

Full chart

Market Stats

Previous Close70.00
Open71.00
Day Range69.90 – 74.10
52-Week Range75.10 – 188.00
Volume6.82M
Market Cap124.35B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.17
Dividend Yield0.00%
Beta1.09
50-Day Avg94.38
200-Day Avg115.90

About

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Vivian Ling
  • Employees0
  • HeadquartersNo.99, Xintai 5th Road, New Taipei City, Taiwan, 221, Taiwan
  • Websitehttps://www.caliway.com.tw

Leadership

  • Mr. Antony HsuPresident, Chief Strategy Officer & Chairman
  • Ms. Vivian LingCEO and Chief R&D Officer
  • Ms. Ellen ChangFinance & Accounting Director and Spokesperson

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue18.63M10.34M12.32M12.83M38.88M44.36M37.98M
Growth (%)--44.51%+19.17%+4.10%+203.12%+14.08%-14.39%
Cost of Revenue7.83M3.67M3.10M28.57M11.45M43.11M11.50M
Gross Profit10.80M6.67M9.22M-15.74M27.44M1.25M26.48M
Gross Margin57.96%64.49%74.83%-122.68%70.56%2.83%69.72%
Operating Expense132.82M112.17M239.65M304.09M540.27M717.21M732.57M
Operating Income-122.02M-105.50M-230.43M-319.82M-512.84M-715.96M-706.09M
Operating Margin-654.87%-1020.30%-1869.95%-2493.17%-1318.88%-1613.95%-1859.31%
EBITDA-106.60M-94.34M-214.21M-302.55M-493.07M-686.50M-683.54M
EBITDA Margin-572.10%-912.36%-1738.34%-2358.53%-1268.05%-1547.55%-1799.94%
Net Income-121.72M-98.39M-224.00M-286.33M-487.85M-587.85M-351.35M
Net Income Margin-653.27%-951.56%-1817.77%-2232.10%-1254.64%-1325.18%-925.20%
R&D109.04M88.90M180.38M295.20M503.37M649.04M649.49M
R&D as % of Total Revenue585.20%859.74%1463.79%2301.23%1294.54%1463.11%1710.27%
Interest Expense--2.90M668.40K497.37K331.43K155.72K
Interest Expense % of Total Revenue--23.56%5.21%1.28%0.75%0.41%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets170.19M226.84M711.96M1.23B3.83B9.77B301.89M
Total Liabilities179.49M180.29M68.15M68.82M85.55M73.69M2.03M
Total Equity-9.30M46.55M643.81M1.16B3.74B9.70B299.86M
Cash21.67M93.47M594.12M655.05M3.42B6.90B25.00M
Total Debt155.32M130.64M36.73M28.68M20.46M11.87M95.53K
Net Debt133.65M37.17M-557.39M-626.37M-3.40B-6.89B-24.90M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-106.44M-47.19M-110.55M-242.76M-423.94M-522.31M-425.90M
Investing Cash Flow-13.38M-2.30M-14.88M-470.54M157.09M-2.49B-5.62B
Financing Cash Flow106.04M122.62M625.98M771.72M3.03B6.49B-119.11M
Capital Expenditure13.22M2.30M14.88M14.16M9.69M11.09M17.14M
Free Cash Flow-119.66M-49.50M-125.43M-256.93M-433.62M-533.40M-443.04M
FCF to OCF112.42%104.88%113.46%105.83%102.29%102.12%104.02%

Earnings

Report DateNov 13, 2024Feb 13, 2025May 8, 2025Aug 11, 2025Nov 10, 2025Mar 9, 2026Mar 31, 2026Aug 11, 2026
EPS Estimate-0.13-0.12-0.16-0.13-0.19-0.17-0.172.93
EPS Actual-0.10-0.03-0.11-0.16-0.010.05-0.07-0.14
Surprise23.08%75.00%31.25%-23.08%94.74%129.41%58.82%-104.78%
TimingPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap124.35B
Enterprise Value121.50B
Trailing P/E0.00
Forward P/E0.00
Price / Sales4230.54
Price / Book13.62
EPS-0.17
Book Value5.92
Revenue (TTM)29.39M
Gross Profit (TTM)20.66M
EBITDA-808.57M
Profit Margin0.00%
Operating Margin-7377.59%
Return on Equity-2.77%
Return on Assets-5.49%
Shares Outstanding1.56B
Shares Float1.15B
Beta1.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 14, 202510000:1000